Immune Modulation of Monocytes Dampens the IL-17+ γδ T cell Response and Associated Psoriasis Pathology in Mice

Psoriasis is a chronic inflammatory condition of the skin, autoimmune in nature, that affects millions of people worldwide. It is driven by IL-17-producing CD4 and γδ-T cells and targeted by current anti-IL-17 or anti-IL-23 monoclonal antibody therapies. These treatments are expensive, increase the risk of opportunistic infections and do not specifically target the inflammatory cascade. Other cells, including inflammatory monocytes have been shown to migrate to psoriatic plaques in both human disease and the imiquimod (IMQ)-induced mouse model and could thus constitute potential alternative therapeutic targets.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Original Article Source Type: research